Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 79 of the 81 references it cites were found in a registry or an index; 19 of the 88 sources its claims cite were checked for support.

The Ocular Gene Delivery Landscape

Open access
Sahu, Bhubanananda, Chug, Isha, Khanna, Hemant · 2021 · Biomolecules

Abstract

The eye is at the forefront of developing therapies for genetic diseases. With the FDA approval of the first gene-therapy drug for a form of congenital blindness, numerous studies have been initiated to develop gene therapies for other forms of eye diseases. These examinations have revealed new information about the benefits as well as restrictions to using drug-delivery routes to the different parts of the eye. In this article, we will discuss a brief history of gene therapy and its importance to the eye and ocular delivery landscape that is currently being investigated, and provide insights into their advantages and disadvantages. Efficient delivery routes and vehicle are crucial for an effective, safe, and longer-lasting therapy.

Overview

CoChat Summary

TL;DR

This review surveys ocular gene delivery, comparing intravitreal, subretinal, and suprachoroidal routes and non-viral versus viral vectors for retinal gene therapy. It concludes that rAAVs are currently the safest and most reliable vehicles, while non-viral systems offer payload and immunogenicity advantages but remain untested in ocular clinical trials.

Key findings

  • The retina can be accessed via three routes—intravitreal, subretinal, and suprachoroidal—with choice depending on target cell type. Subretinal injection is invasive and carries risks of retinal tears, detachments, and macular holes; intravitreal injection is safer but poorly transduces the outer retina due to the inner limiting membrane and vitreous; suprachoroidal injection is less invasive but requires specialized needles and AAV vectors struggle to traverse the choroid to reach RPE and photoreceptors.
  • Over 300 genes are associated with inherited retinal degenerations (IRDs), and >3 million people in the United States have vision impairment, expected to double to ~6 million by 2050.
  • Non-viral vectors include lipid-, peptide-, polymer-based nanoparticles and naked DNA. They can accommodate large plasmid DNA, are less immunogenic, carry no insertional mutagenesis risk, and have low production cost; ECO nanoparticles delivered RPE65 in Rpe65−/− mice, and CK30-PEG-compacted nanoparticles transfected RPE and photoreceptors and treated Rpe65−/− and Abca4−/− mice. However, non-viral ocular gene delivery has not yet entered clinical trials for ocular diseases.
  • Viral vectors differ in packaging capacity: retrovirus 8 kb, lentivirus 8–9 kb, adenovirus 30–40 kb (about 18.5% of clinical trials use adenoviral vectors), and AAV genome 4.7 kb with therapeutic payload under 5 kb. rAAV capsid engineering—AAV8, AAV8(Y733F), AAV7m8, AAV8BP2, and AAV-PHP.eB—improves retinal tropism; Luxturna was FDA-approved in 2018. rAAV limitations include immune responses, neutralizing antibodies, and <5 kb packaging capacity.

Methods

  • Narrative review; no primary experimental design, sample, or statistical analysis is reported. It synthesizes literature on gene therapy history, retinal disease genetics, ocular delivery routes, and vector classes.
  • Discusses non-viral vectors (lipid-based, peptide-based, polymer-based, naked DNA) and viral vectors (retroviral, lentiviral, adenoviral, AAV), citing animal-model and clinical-trial examples.
  • No systematic search strategy, inclusion criteria, or meta-analysis is described.

Limitations

  • The paper does not state limitations of its own review. Evident from the text: it is a narrative review without systematic search criteria, quantitative synthesis, or formal risk-of-bias assessment.
  • Field limitations stated in the paper include anatomical barriers in the retina and pH sensitivity of nanoparticles that hinder efficient non-viral delivery and prolonged gene expression; species-specific differences mean promising rodent results may not hold in larger species such as sheep, pigs, and non-human primates.
  • rAAV limitations stated include intraocular inflammation, loss of efficacy, neutralizing antibodies against capsids, and limited transgene size (<5 kb), with dual AAV vector systems and nanoparticles being developed as alternatives.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/biom11081135

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Drug delivery routes. Ocular delivery routes at the indicated locations are depicted. RPE: retinal pigment epithelium.
Figure 1 Drug delivery routes. Ocular delivery routes at the indicated locations are depicted. RPE: retinal pigment epithelium.CC BY · PubMed Central
Figure 2 Schematic representation of the major subtypes of the ocular gene delivery vectors.
Figure 2 Schematic representation of the major subtypes of the ocular gene delivery vectors.CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 3 Not valid · 53 Not checked · 16 Own results and interpretations

36 more claims · 4 with their cited sources checked

Create a free account to see all 83 claims and to verify the 69 references still open.

See all claims — free account
  • It may state two separate claims as one. 23
  • Probably not a substantial claim. 23

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 81 references

Research works printed but not linked: 2

  1. Kandel, E.R. (2013). Principles of Neural Science, McGraw-Hill. [5th ed.].
  2. Audo, 2015, Early findings in a phase I/IIa clinical program for stargardt disease (STGD1, MIM # 248200), Invest. Ophthalmol. Vis. Sci., 56, 3819

Cited by

See all 30

Metadata

Authors
Sahu, B., Chug, I., & Khanna, H.
Affiliations
University of Massachusetts Chan Medical School (US)
Corresponding author
Khanna, Hemant
Venue
Biomolecules
Publisher
MDPI AG
Published
2021-08-01
Volume
11
Issue
8
Pages
1135
ISSN
2218-273X (ISSN-L)
OpenAlex
W3191982495
Cited by
28
References
81
Citations by year
2026: 3 · 2025: 5 · 2024: 9 · 2023: 7 · 2022: 2 · 2021: 2
FWCI
0.46
Type
journal article
Language
en
Open access
Locations
  • Biomolecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Eye Institute (EY022372)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
Keywords
ocular gene therapy, ocular drug delivery, eye diseases, congenital blindness, history of gene therapy
MeSH terms
Choroidal Effusions, Animals, DNA, Eye, Eye Diseases, Genetic Vectors, Humans, Liposomes, Peptides, Viruses, Vitreous Body, Genetic Therapy, Gene Transfer Techniques, Nanoparticles, Intravitreal Injections, Subretinal Fluid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Ocular Gene Delivery Landscape. https://app.cochat.ai/papers/10.3390/biom11081135
The paper
Sahu, B., Chug, I., & Khanna, H. (2021). The Ocular Gene Delivery Landscape. Biomolecules. https://doi.org/10.3390/biom11081135

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.